Female
sexual dysfunction (FSD) prevents the females to experience satisfaction from the
sexual activity. FSD can be developed during any phase of the sexual response
cycle which consists of excitement, plateau, orgasm and resolution phases.
Access
More About This Research at:
Sexual
dysfunction is more common in women than in men. There are several medical
conditions including heart diseases, diabetes, hormonal imbalances,
neurological diseases, kidney diseases, alcohol consumption, depression,
anxiety and drug abuse that leads to FSD.
Request
to Get the Sample Pages at:
There are
several problems associated with FSD such as inhibited sexual desire, inability
to become aroused, lack of orgasm and painful intercourse. S1 Biopharma Inc. is
developing LOREXYS as an oral, non-hormonal, fixed-dose combination of two
antidepressants (bupropion and trazodone) for the treatment of hypoactive
sexual desire disorder (HSDD) in women. Acerus Pharmaceuticals Corporation, and
Palatin Technologies Inc. are some other key players having pipeline products
for the treatment of FSD.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment